GE Healthcare has roped in Manipal Health Systems as its India partner for its ongoing global clinical studies on its diagnostic products.
These are imaging agents being tested for diagnosis in oncology, neurology and cardiology. In the study starting in September, a GE integrated development centre (IDC) equipped with GE medical devices are to be set up at Manipal Hospital, Bangalore.
Using its doctors as investigators, Manipal will conduct 1,000 scans a year, initially contracted for three years, and return the raw data from these imagings to GE. The data from the first IDC in Bangalore would be part of a series of worldwide clinical trials spread across the US, European countries and Latin America.
MEMG would invest around Rs 35 crore in the equipment for the IDC.
The trials will use GEs scanners, viz. LightSpeed VCT, PET/CT scanner, dual head gamma camera with CT and twin speed high-definition MR imaging. The hospitals chain of the Rs 280-crore Manipal Health Systems would be referral points. Only 28 June 2006, Manipal announced a Rs 90-crore infusion by IDFC Private Equity Fund into its health systems.
The first studies will be on the agent Visipaque (iodixanol) that GE launched in 1996 and used in X-ray and CT scans.
|
|
|
|
|
| Posted : 6/30/2006 |
|
|
|
|
